Ex-Seres Executive Roger Pomerantz Appointed ContraFect CEO

Roger Pomerantz is now chairman and CEO of infectious diseases drug developer ContraFect (NASDAQ: [[ticker:CFRX]]). He succeeds Steven Gilman, who is retiring. Pomerantz has been vice chairman of Yonkers, NY-based ContraFect for five years. He was also CEO of Cambridge, MA-based microbiome drug developer Seres Therapeutics (NASDAQ: [[ticker:MCRB]]) from 2014 until January of this year. ContraFect’s lead drug candidate, exebacase, is in mid-stage testing as a treatment for Staphylococcus aureus bacteria in the blood.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.